- Home
- HRMY vs TRMD Comparison
HRMY vs TRMD Comparison
Compare HRMY & TRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | TRMD |
|---|---|---|
| Founded | 2017 | 1889 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | TRMD |
|---|---|---|
| Price | $37.82 | $19.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $51.33 | $23.00 |
| AVG Volume (30 Days) | ★ 695.1K | 425.0K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 10.34% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 2.76 |
| Revenue | $825,944,000.00 | ★ $1,292,300,000.00 |
| Revenue This Year | $23.11 | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | $12.04 | ★ $7.18 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $13.60 |
| 52 Week High | $40.93 | $23.67 |
Technical Indicators
Market Signals| Indicator | HRMY | TRMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 41.34 |
| Support Level | $37.12 | $19.30 |
| Resistance Level | $39.60 | $20.91 |
| Average True Range (ATR) | 1.15 | 0.33 |
| MACD | -0.38 | -0.04 |
| Stochastic Oscillator | 17.33 | 39.75 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.